HFB-1002(HiFiBiO Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHFB-1002(HiFiBiO Therapeutics)
Drug Alias NameAnti-hCXCR5 blockerHFB1002 seriesHFB-1002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionC-X-C motif chemokine receptor 5 antagonistsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsC-X-C motif chemokine receptor 5
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHiFiBiO Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesFibrogen IncHiFiBiO Therapeutics
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A